Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: US$500.2M · US$35.5 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), Morgan Stanley (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead) Use of proceeds: Pre-commercial activities for avexitide including manufacturing capacity, research and development, working capital and general corporate purposes | Aug 20, 2026 |
| Public offering of common stock Announced: US$175M · US$10 a share · Leerink Partners +2 Dealers: Leerink Partners (lead), Guggenheim Securities (lead), H.C. Wainwright & Co. (lead) Use of proceeds: Avexitide commercial readiness, research and development, working capital and general corporate purposes | Sep 10, 2025 |
| Public offering of common stock Announced: about US$60M · US$3.5 a share · Leerink Partners Dealers: Leerink Partners (lead) Use of proceeds: Advance preparations for commercialization and pipeline programs, working capital and general corporate purposes | Jan 10, 2025 |